Is Uber Stock a Buy, Sell or Hold?
Uber (NYSE:UBER) has been through quite a ride over the…
Sell
11
UTMD Quote, Financials, Valuation and Earnings
Last price:
$52.29
Seasonality move
:
3.39%
Day range:
$52.27 - $52.75
52-week range:
$52.27 - $77.33
Dividend yield:
2.31%
P/E ratio:
13.25x
P/S ratio:
4.48x
P/B ratio:
1.46x
Volume:
10.9K
Avg. volume:
18.6K
1-year change:
-22.66%
Market cap:
$171.6M
Revenue:
$40.9M
EPS (TTM):
$3.95
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Utah Medical Products has -- downside to fair value with a price target of -- per share.
UTMD vs. S&P 500
-
Over the past 5 trading days, Utah Medical Products has overperformed the S&P 500 by 0.38% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Utah Medical Products does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Utah Medical Products revenues have been falling on a year-over-year basis for 7 quarters in a row. In the most recent quarter Utah Medical Products reported revenues of $9.2M.
Earnings Growth
-
Utah Medical Products earnings have been falling on a year-over-year basis for 6 quarters in a row. In the most recent quarter Utah Medical Products reported earnings per share of $0.86.
Enterprise value:
88.7M
EV / Invested capital:
--
Price / LTM sales:
4.48x
EV / EBIT:
6.18x
EV / Revenue:
2.17x
PEG ratio (5yr expected):
--
EV / Free cash flow:
6.07x
Price / Operating cash flow:
12.55x
Enterprise value / EBITDA:
5.16x
Gross Profit (TTM):
$24.1M
Return On Assets:
10.62%
Net Income Margin (TTM):
33.92%
Return On Equity:
11.16%
Return On Invested Capital:
11.16%
Operating Margin:
31.99%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $52.3M | $50.2M | $40.9M | $12.3M | $9.2M | |
| Gross Profit | $32.2M | $30M | $24.1M | $7.1M | $5.3M | |
| Operating Income | $19.8M | $17.2M | $14.3M | $3.9M | $2.9M | |
| EBITDA | $26.9M | $23.6M | $17.2M | $5M | $3.7M | |
| Diluted EPS | $4.51 | $4.57 | $3.95 | $1.18 | $0.86 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $62.3M | $73.2M | $89.9M | $106.3M | $96.3M | |
| Total Assets | $111.7M | $115.6M | $123.9M | $135.5M | $122.5M | |
| Current Liabilities | $3.8M | $3.7M | $6M | $4.7M | $3.8M | |
| Total Liabilities | $8.9M | $8.5M | $9.6M | $7.1M | $5.1M | |
| Total Equity | $102.8M | $107.1M | $114.3M | $128.3M | $117.4M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $21.1M | $22.3M | $14.8M | $5.3M | $2.9M | |
| Cash From Investing | -$818K | -$639K | -$208K | -$90K | -$9K | |
| Cash From Financing | -$5.5M | -$4.2M | -$23.8M | -$1.1M | -$7.7M | |
| Free Cash Flow | $20.3M | $21.6M | $14.6M | $5.2M | $2.9M | |
UTMD
Sector
Market Cap
$171.6M
$35M
Price % of 52-Week High
67.63%
41.88%
Dividend Yield
2.31%
0%
Shareholder Yield
11.7%
-0.91%
1-Year Price Total Return
-22.66%
-43.29%
Beta (5-Year)
0.171
0.743
Dividend yield:
2.31%
Annualized payout:
$1.21
Payout ratio:
30.71%
Growth streak:
2 years
Technicals
8-day SMA
Sell
Level
$53.22
200-day SMA
Sell
Level
$63.64
Bollinger Bands (100)
Sell
Level
56.83 - 63.51
Chaikin Money Flow
Sell
Level
-577.7K
20-day SMA
Sell
Level
$54.94
Relative Strength Index (RSI14)
Sell
Level
24.05
ADX Line
Sell
Level
15.48
Williams %R
Buy
Level
-99.397
50-day SMA
Sell
Level
$57.61
MACD (12, 26)
Sell
Level
-1.50
25-day Aroon Oscillator
Sell
Level
-88
On Balance Volume
Neutral
Level
1.3M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (27.1512)
Buy
CA Score
(Annual)
Level (2.2115)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-9.5094)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.
Stock Forecast FAQ
In the current month, UTMD has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The UTMD average analyst price target in the past 3 months is --.
-
Where Will Utah Medical Products Stock Be In 1 Year?
According to analysts, the consensus estimate is that Utah Medical Products share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Utah Medical Products?
Analysts are divided on their view about Utah Medical Products share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Utah Medical Products is a Sell and believe this share price will rise from its current level to --.
-
What Is Utah Medical Products's Price Target?
The price target for Utah Medical Products over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is UTMD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Utah Medical Products is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of UTMD?
You can purchase shares of Utah Medical Products via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Utah Medical Products shares.
-
What Is The Utah Medical Products Share Price Today?
Utah Medical Products was last trading at $52.29 per share. This represents the most recent stock quote for Utah Medical Products. Yesterday, Utah Medical Products closed at $52.30 per share.
-
How To Buy Utah Medical Products Stock Online?
In order to purchase Utah Medical Products stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Micron a Good Stock to Buy Now?
Like most of its peers in the semiconductor industry, Micron…
Is Uber Finally on the Path to Consistent Profitability?
After posting massive losses quarter after quarter for years, Uber…
Stock Ideas
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 32x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 31x
Sell
46
Is NVDA Stock a Buy?
Market Cap: $2.5T
P/E Ratio: 35x
Alerts
Sell
32
MAN alert for Apr 18
ManpowerGroup [MAN] is down 19.07% over the past day.
Sell
24
GPN alert for Apr 18
Global Payments [GPN] is down 17.44% over the past day.
Buy
51
CAR alert for Apr 18
Avis Budget Group [CAR] is up 16.54% over the past day.
